BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gotoh L, Yamada M, Hattori K, Sasayama D, Noda T, Yoshida S, Kunugi H, Yamada M. Levels of lysophosphatidic acid in cerebrospinal fluid and plasma of patients with schizophrenia. Psychiatry Res 2019;273:331-5. [PMID: 30682553 DOI: 10.1016/j.psychres.2019.01.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 García-Marchena N, Pizarro N, Pavón FJ, Martínez-Huélamo M, Flores-López M, Requena-Ocaña N, Araos P, Silva-Peña D, Suárez J, Santín LJ, de la Torre R, Rodríguez de Fonseca F, Serrano A. Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients. Sci Rep 2020;10:17163. [PMID: 33051508 DOI: 10.1038/s41598-020-74155-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Bari S, Sultana S, Daria S, Proma MA, Islam MR, Haque MA. Lysophosphatidic acid and lysophosphatidylcholine levels in serum samples of patients with major depressive disorder.. [DOI: 10.1101/2020.10.04.20206490] [Reference Citation Analysis]
3 Gotoh L, Yamada M, Hattori K, Sasayama D, Noda T, Yoshida S, Kunugi H, Yamada M. Lysophosphatidic acid levels in cerebrospinal fluid and plasma samples in patients with major depressive disorder. Heliyon 2019;5:e01699. [PMID: 31193411 DOI: 10.1016/j.heliyon.2019.e01699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]